Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Suspended 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1

Conditions

Turcot syndrome 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 213Cyclophosphamide 123Nivolumab 110Carboplatin 94fludarabine 81Gemcitabine 78Specimen Handling 74Bevacizumab 73Injections 71venetoclax 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 54Ipilimumab 50Temozolomide 46Lenalidomide 43Azacitidine 43Docetaxel 42Pemetrexed 41Rituximab 40Radiotherapy 40Oxaliplatin 40Fluorouracil 39Cetuximab 38durvalumab 37Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × E7777 fusion protein × 1 year × Clear all
NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

University of Pittsburgh

Phase 1/2 Active not recruiting
25 enrolled
Gynecologic

Turcot syndrome, Carcinoma, Ovarian Epithelial

NCT04855253 2026-01-15

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Masonic Cancer Center, University of Minnesota

Phase 1/2 Suspended
30 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡